IRLAB Therapeutics AB (OSTO:IRLAB A) Debt-to-Asset : 0.20 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Debt-to-Asset?

IRLAB Therapeutics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr2.07 Mil. IRLAB Therapeutics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr25.54 Mil. IRLAB Therapeutics AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr136.67 Mil. IRLAB Therapeutics AB's debt to asset for the quarter that ended in Mar. 2024 was 0.20.

IRLAB Therapeutics AB Debt-to-Asset Historical Data

The historical data trend for IRLAB Therapeutics AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Debt-to-Asset Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.01

0.16

IRLAB Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.16	0.20

Competitive Comparison of IRLAB Therapeutics AB's Debt-to-Asset

For the Biotechnology subindustry, IRLAB Therapeutics AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Debt-to-Asset falls into.

IRLAB Therapeutics AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

IRLAB Therapeutics AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.94	+	24.626)	/	177.121
	=	0.16

IRLAB Therapeutics AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.067	+	25.54)	/	136.667
	=	0.20

IRLAB Therapeutics AB (OSTO:IRLAB A) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

IRLAB Therapeutics AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

6IRA:Germany

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines